[1] |
SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30.
|
[2] |
YAN M,PARKER B A,SCHWAB R,et al.HER2 aberrations in cancer:implications for therapy[J]. Cancer Treat Rev,2014,40(6):770-780.
|
[3] |
EKMAN S.HER2:defining a Neu target in non-small-cell lung cancer[J]. Ann Oncol,2019,30(3):353-355.
|
[4] |
金姝,朱琪,秦华晖,等. 乳腺癌C-erbB-2蛋白表达与基因CpG岛甲基化状态和mRNA表达的关系[J]. 检验医学,2011,26(11):750-755.
|
[5] |
PEROU C M,SØRLIE T,EISEN M B,et al. Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
|
[6] |
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature,2012,490(7418):61-70.
|
[7] |
PARKER J S,MULLINS M,CHEANG M C,et al.Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol,2009,27(8):1160-1167.
|
[8] |
DABBS D J,KLEIN M E,MOHSIN S K,et al.High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test:an independent quality assurance study[J]. J Clin Oncol,2011,29(32):4279-4285.
|
[9] |
MOUTTET D,LAÉ M,CALY M,et al.Estrogen-receptor,progesterone-receptor and HER2 status determination in invasive breast cancer. Concordance between immuno-histochemistry and MapQuantTM microarray based assay[J]. PLoS One,2016,11(2):e0146474.
|
[10] |
DENKERT C,LOIBL S,KRONENWETT R,et al.RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy[J]. Ann Oncol,2013,24(3):632-639.
|
[11] |
KHALED N,BIDET Y.New insights into the implication of epigenetic alterations in the EMT of triple negative breast cancer[J]. Cancers(Basel),2019,11(4):559.
|
[12] |
DWORKIN A M,HUANG T H,TOLAND A E.Epigenetic alterations in the breast:implications for breast cancer detection,prognosis and treatment[J]. Semin Cancer Biol,2009,19(3):165-171.
|
[13] |
GUY C T,WEBSTER M A,SCHALLER M,et al.Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease[J]. Proc Natl Acad Sci U S A,1992,89(22):10578-10582.
|
[14] |
ZHOU H,CHEN W D,QIN X,et al.MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice[J]. Oncogene,2001,20(42):6009-6017.
|
[15] |
FREUDENBERG J A,WANG Q,KATSUMATA M,et al.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies[J]. Exp Mol Pathol,2009,87(1):1-11.
|
[16] |
YAN P S,VENKATARAMU C,IBRAHIM A,et al.Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue[J]. Clin Cancer Res,2006,12(22):6626-6636.
|
[17] |
POLYAK K.Breast cancer:origins and evolution[J]. J Clin Invest,2007,117(11):3155-3163.
|
[18] |
DWORKIN A M,HUANG T H,TOLAND A E.Epigenetic alterations in the breast:implications for breast cancer detection,prognosis and treatment[J]. Semin Cancer Biol,2009,19(3):165-171.
|
[19] |
SIMONOVA O,KUZNETSOVA E,TANAS A S,et al.Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer[J]. Ann Oncol,2019,30(Suppl 5):v6.
|
[20] |
LIU Q,KULAK M V,BORCHERDING N,et al.A novel HER2 gene body enhancer contributes to HER2 expression[J]. Oncogene,2018,37(5):687-694.
|
[21] |
LINDQVIST B M,WINGREN S,MOTLAGH P B,et al.Whole genome DNA methylation signature of HER2-positive breast cancer[J]. Epigenetics-US,2014,9(8):1149-1162.
|